CNS Drugs

, Volume 25, Issue 9, pp 803–813

Quetiapine Extended Release

Adjunctive Treatment in Major Depressive Disorder
Adis Drug Profile


Quetiapine extended release (XR) is a once-daily oral formulation of the atypical antipsychotic quetiapine that is available for use as adjunctive therapy in major depressive disorder (MDD).

Systemic quetiapine exposure after orally administered quetiapine XR is similar to that of quetiapine immediate release at the same dosage, although quetiapine XR is absorbed more slowly and plasma concentrations are more stable over time.

In two 6-week, randomized, double-blind, placebo-controlled, multinational trials in patients with MDD with an inadequate response to antidepressants, quetiapine XR 300 mg/day adjunctive to antidepressant reduced depressive symptoms significantly more than antidepressant plus placebo, according to changes in Montgomery-Åsberg Depression Rating Scale (MADRS) total scores. In one trial, adjunctive quetiapine XR 150mg/day also led to significantly greater reductions in MADRS total scores than antidepressant plus placebo.

MDD response rates were significantly higher with adjunctive quetiapine XR 300 mg/day (but not 150 mg/day) than with antidepressant plus placebo. The numbers needed to treat to achieve an additional response over antidepressant plus placebo were 11–18 and 8–9 in the quetiapine XR 150 and 300 mg/day dosage groups, respectively.

Treatment-emergent adverse events were mostly of mild to moderate severity; 1% of adjunctive quetiapine XR and 1.3% of antidepressant plus placebo recipients reported serious adverse events.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003 Jun 18; 289 (23): 3095–105PubMedCrossRefGoogle Scholar
  2. 2.
    World Health Organization. The global burden of disease: 2004 update [online]. Available from URL: [Accessed 2011 Mar 7]
  3. 3.
    Janicak PG, Dowd SM. Treatment-resistant depression: an update on diagnosis and management. Psychopharm Rev 2009; 44 (6): 41–8Google Scholar
  4. 4.
    Mann JJ. The medical management of depression. N Engl J Med 2005; 353 (17): 1819–34PubMedCrossRefGoogle Scholar
  5. 5.
    Davidson JRT. Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry 2010; 71 Suppl. E1: e04PubMedCrossRefGoogle Scholar
  6. 6.
    Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009 Sep; 166 (9): 980–91PubMedCrossRefGoogle Scholar
  7. 7.
    European Medicines Agency. Questions and answers on Seroquel XR and associated names (50, 150, 200, 300 and 400 mg prolonged-release tablets containing quetiapine): outcome of a procedure under Article 6(13) of Regulation (EC) 1084/2003 as amended. Available from URL: [Accessed 2010 Jul 14]
  8. 8.
    The electronic Medicines Compendium (eMC). Seroquel XR 50mg, 150mg, 200mg, 300mg, 400mg prolonged-release tablets: summary of product characteristics [online]. Available from URL: [Accessed 2011 Feb 8]
  9. 9.
    AstraZeneca. Seroquel XR (quetiapine fumarate) tablets: prescribing information [online]. Available from URL: [Accessed 2011 Jul 21]
  10. 10.
    McIntyre RS, Soczynska JK, Woldeyohannes HO, et al. A preclinical and clinical rationale for quetiapine in mood syndromes. Expert Opin Pharmacother 2007 Jun; 8 (9): 1211–9PubMedCrossRefGoogle Scholar
  11. 11.
    Nyberg S, Widzowski D. Translational pharmacology of quetiapine and norquetiapine: preclinical findings support multifunctional psychotropic properties [abstract no. PW01–27]. Eur Psychiatry 2010; 25 Suppl. 1: 1446CrossRefGoogle Scholar
  12. 12.
    Jensen NH, Rodriguiz RM, Caron MG, et al. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine’s antidepressant activity. Neuropsychopharmacol 2008 Sep; 33 (10): 2303–12CrossRefGoogle Scholar
  13. 13.
    Nyberg S, Takano A, Jucaite A, et al. PET-measured occupancy of the norepinephrene transporter by extended release quetiapine fumarate (quetiapine XR) in brains of healthy subjects [abstract no. P.1.e.019]. Eur Neuropsychopharmacol 2008; 18 Suppl. 4: S270CrossRefGoogle Scholar
  14. 14.
    Datto C, Berggren L, Patel JB, et al. Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects. Clin Ther 2009 Mar; 31 (3): 492–502PubMedCrossRefGoogle Scholar
  15. 15.
    Nord M, Nyberg S, Brogren J, et al. Comparison of D2 dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects. Int J Neuropsychopharmacol. Epub 2011 Apr 11Google Scholar
  16. 16.
    Mamo DC, Uchida H, Vitcu I, et al. Quetiapine extended-release versus immediate-release formulation: a positron emission tomography study. J Clin Psychiatry 2008; 69 (1): 81–6PubMedCrossRefGoogle Scholar
  17. 17.
    Gedge L, Lazowski L, Murray D, et al. Effects of quetiapine on sleep architecture in patients with unipolar or bipolar depression. Neuropsychiatric Dis Treat 2010; 6 (1): 501–8Google Scholar
  18. 18.
    De Vane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet 2001; 40 (7): 509–22CrossRefGoogle Scholar
  19. 19.
    Wang J-S, Zhu H-J, Markowitz JS, et al. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology 2006 Sep; 187 (4): 415–23PubMedCrossRefGoogle Scholar
  20. 20.
    Figueroa C, Brecher M, Hamer-Maansson JE, et al. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog Neuropsychopharmacol Biol Psychiatry 2009 Mar 17; 33 (2): 199–204PubMedCrossRefGoogle Scholar
  21. 21.
    Bauer M, Pretorius HW, Constant EL, et al. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 2009 Apr; 70 (4): 540–9PubMedCrossRefGoogle Scholar
  22. 22.
    El-Khalili N, Joyce M, Atkinson S, et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2010; 13 (7): 917–32PubMedCrossRefGoogle Scholar
  23. 23.
    Bauer M, El-Khalili N, Datto C, et al. A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. J Affect Disord 2010 Dec; 127 (1–3): 19–30PubMedCrossRefGoogle Scholar
  24. 24.
    Bandelow B, Bauer M, Vieta E, et al. Pooled analysis of the efficacy of adjunctive quetiapine XR in patients with major depressive disorder and high or low levels of baseline anxiety [abstract no. P06]. Int J Psychiat Clin Pract 2010; 14 Suppl. 1: 19Google Scholar
  25. 25.
    Bauer M, Dell’Osso L, Kasper S, et al. Quetiapine XR monotherapy, quetiapine XR+ongoing antidepressants and lithium+ongoing antidepressants in patients with treatment-resistant major depressive disorder [abstract no. p-09.004]. Int J Neuropsychopharmacol 2010; 13 Suppl. 1: 143Google Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  1. 1.Adis, a Wolters Kluwer BusinessMairangi Bay, North Shore 0754, AucklandNew Zealand

Personalised recommendations